GS-621763 clinical trials
Also written VV116 and JT001.
How each study uses GS-621763 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2022 (5)
| Year | Studies |
|---|---|
| 2021 | 4 |
| 2022 | 5 |
| 2023 | 5 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 0
Vigonvita Life Sciences (7) · Shanghai Vinnerna Biosciences Co., Ltd. (7) · Shanghai JunTop Biosciences Co., LTD (1) · Jeil Pharmaceutical Co., Ltd. (1)
Studies
Open first, then newest update. How each study uses GS-621763 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 16
- A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSVCompletedPhase 2Vigonvita Life SciencesNCT06206720Written as Deuremidevir Hydrobromide for SuspensionHow we know
- The Mass Balance Study of [14C]JT001CompletedPhase 1Shanghai Vinnerna Biosciences Co., Ltd.NCT05802810Written as [14C]JT001How we know
- A Study to Evaluate the Bioavailability, Food Effect and Pharmacokinetics of Deuremidevir Hydrobromide for SuspensionCompletedPhase 1Vigonvita Life SciencesNCT05932459Written as Deuremidevir Hydrobromide for Suspension 100mgHow we know
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for SuspensionCompletedPhase 1Vigonvita Life SciencesNCT06328400Written as Deuremidevir Hydrobromide for SuspensionHow we know
- A Study in Subjects With Liver Function Injury and Subjects With Normal Liver FunctionCompletedPhase 1Shanghai Vinnerna Biosciences Co., Ltd.NCT06093230Written as Deuremidevir Hydrobromide TabletsHow we know
- A Study in Elderly Chinese Subjects With Underlying DiseasesCompletedPhase 1Shanghai Vinnerna Biosciences Co., Ltd.NCT06093308Written as Deuremidevir Hydrobromide TabletsHow we know
- A Study in Subjects With Renal Impairment Compared to Subjects With Normal Renal FunctionCompletedPhase 1Shanghai Vinnerna Biosciences Co., Ltd.NCT05895812Written as Deuremidevir Hydrobromide TabletsHow we know
- JT001 (VV116) for the Early Treatment of COVID-19TerminatedPhase 2/3Shanghai JunTop Biosciences Co., LTDNCT05242042Written as JT001How we know
- JT001 (VV116) for the Treatment of COVID-19CompletedPhase 3Shanghai Vinnerna Biosciences Co., Ltd.NCT05582629Written as JT001How we know
- Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 TabletsWithdrawnPhase 1Shanghai Vinnerna Biosciences Co., Ltd.NCT05355077Written as JT001 200mg BidHow we know
- Efficacy and Safety of JT001 (VV116) Compared With FavipiravirTerminatedPhase 3Shanghai Vinnerna Biosciences Co., Ltd.NCT05279235Written as JT001How we know
- Efficacy and Safety of JT001 (VV116) Compared With PaxlovidCompletedPhase 3Vigonvita Life SciencesNCT05341609Written as JT001How we know
- Safety and Pharmacokinetics Study of Single Ascending Doses of VV116 in Healthy VolunteersCompletedPhase 1Vigonvita Life SciencesNCT05227768Written as VV116 25mg GroupHow we know
- To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and DapagliflozinStatus unknownPhase 3Jeil Pharmaceutical Co., Ltd.NCT05101135Written as JT-001How we know
- Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV116 in Healthy VolunteersCompletedPhase 1Vigonvita Life SciencesNCT05201690Written as VV116 200 mg GroupHow we know
- Food Effect on Pharmacokinetic Profiles of VV116 Administered Orally to Chinese Healthy VolunteersCompletedPhase 1Vigonvita Life SciencesNCT05221138Written as VV116How we know
Codes
What other systems call GS-621763 · ClinicalTrials.gg INT001875
- MeSH (NLM) C000722705GS-621763One source NLM
- UNII (FDA) 83BU3492RPGS-621763One source NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722705 | GS-621763 | One source NLM |
| UNII (FDA) | 83BU3492RP | GS-621763 | One source NLM |
Also registered as deuremidevir hydrobromide (UNII P4L9Q2T94L) and jt-001 (UNII 43K4X7JG75).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.